[Results in 42 non-resectable NSCLC IIA-B patients with initial concurrent Taxotere-Cisplatin chemoradiotherapy].
| Autor: | Szilasi M; Tüdôgyógyászati Klinika, DE OEC, Debrecen, 4012, Hungary. mszilasi@jaguar.unideb.hu, Horváth A, Dolinay T, Szántó J, Brugós L, Lengyel L, Kiss SS, Kiss M, Adamecz Z |
|---|---|
| Jazyk: | maďarština |
| Zdroj: | Magyar onkologia [Magy Onkol] 2006; Vol. 50 (3), pp. 233-6. Date of Electronic Publication: 2006 Nov 12. |
| DOI: | HUON.2006.50.3.0233 |
| Abstrakt: | Goals: A prospective multicenter study to treat non-small cell lung cancer (NSCLC) with inductive chemoradiotherapy for improving chances of operability. If used as first-line therapy, combined treatment improves survival and it is well tolerated with a low rate of side effects. Patients: 42 patients with stage IIIA-B NSCLC from which 36 could be followed. Methods: A full dose Taxotere-Cisplatin chemotherapy was given to patients with concurrent radiotherapy in 2 Gy fractions up to 60 Gy via conformal irradiation. Results: Local response was very high and 40.47% of patients became operable while in inoperable cases consolidation chemotherapy showed similar results as other protocols. We also found a low rate of side effects. The high rate of brain metastasis suggests that prophylactic cranial irradiation (PCI) should be considered. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|